Other Species / Isoforms
  RNU3IP2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsATAAARK
0 1
RNU3IP2 (human) ______MsATAAARK S2-p
RNU3IP2 (mouse) ______MSTAVATRK S2
RNU3IP2 (rat) ______MSTAVATRK S2
R10-m1
ATAAARKrGkPAsGA
0 4
RNU3IP2 (human) ATAAARKrGkPAsGA R10-m1
RNU3IP2 (mouse) TAVATRKRAKPAPGP R10
RNU3IP2 (rat) TAVATRKRAKPAPGP R10
K12-ac
AAARKrGkPAsGAGA
0 10
RNU3IP2 (human) AAARKrGkPAsGAGA K12-ac
RNU3IP2 (mouse) VATRKRAKPAPGPGA K12
RNU3IP2 (rat) VATRKRAKPAPGPGA K12
K12-ub
AAARKrGkPAsGAGA
0 1
RNU3IP2 (human) AAARKrGkPAsGAGA K12-ub
RNU3IP2 (mouse) VATRKRAKPAPGPGA K12
RNU3IP2 (rat) VATRKRAKPAPGPGA K12
S15-p
RKrGkPAsGAGAGAG
0 1
RNU3IP2 (human) RKrGkPAsGAGAGAG S15-p
RNU3IP2 (mouse) RKRAKPAPGPGAAPV P15
RNU3IP2 (rat) RKRAKPAPGPGAAPV P15
K25-ac
GAGAGAGkRRRKADs
0 90
RNU3IP2 (human) GAGAGAGkRRRKADs K25-ac
RNU3IP2 (mouse) GAAPVAGkrrRKVDS K25-ac
RNU3IP2 (rat) GAAPVDGKRRRKVDS K25
R26
AGAGAGkRRRKADsA
0 1
RNU3IP2 (human) AGAGAGkRRRKADsA R26
RNU3IP2 (mouse) AAPVAGkrrRKVDSA R26-m2
RNU3IP2 (rat) AAPVDGKRRRKVDSA R26
R27
GAGAGkRRRKADsAG
0 1
RNU3IP2 (human) GAGAGkRRRKADsAG R27
RNU3IP2 (mouse) APVAGkrrRKVDSAA R27-m2
RNU3IP2 (rat) APVDGKRRRKVDSAA R27
S32-p
kRRRKADsAGDRGKs
0 1
RNU3IP2 (human) kRRRKADsAGDRGKs S32-p
RNU3IP2 (mouse) krrRKVDSAADRGKS S32
RNU3IP2 (rat) KRRRKVDSAASRGKS S32
S39-p
sAGDRGKsKGGGKMN
0 1
RNU3IP2 (human) sAGDRGKsKGGGKMN S39-p
RNU3IP2 (mouse) SAADRGKSKGGGKMN S39
RNU3IP2 (rat) SAASRGKSKGGGKMN S39
S50-p
GKMNEEIssDsEsEs
0 37
RNU3IP2 (human) GKMNEEIssDsEsEs S50-p
RNU3IP2 (mouse) GKMNEEIssDsEsEs S50-p
RNU3IP2 (rat) GKMNEEISSDSESES S50
S51-p
KMNEEIssDsEsEsL
Upstream
0 42
Treatment
  • nocodazole
RNU3IP2 (human) KMNEEIssDsEsEsL S51-p
RNU3IP2 (mouse) KMNEEIssDsEsEsL S51-p
RNU3IP2 (rat) KMNEEISSDSESESL S51
S53-p
NEEIssDsEsEsLAP
Upstream
0 41
Treatment
  • nocodazole
RNU3IP2 (human) NEEIssDsEsEsLAP S53-p
RNU3IP2 (mouse) NEEIssDsEsEsLAP S53-p
RNU3IP2 (rat) NEEISSDSESESLAP S53
S55-p
EIssDsEsEsLAPRK
0 6
RNU3IP2 (human) EIssDsEsEsLAPRK S55-p
RNU3IP2 (mouse) EIssDsEsEsLAPRK S55-p
RNU3IP2 (rat) EISSDSESESLAPRK S55
S57-p
ssDsEsEsLAPRKPE
0 6
RNU3IP2 (human) ssDsEsEsLAPRKPE S57-p
RNU3IP2 (mouse) ssDsEsEsLAPRKTE S57-p
RNU3IP2 (rat) SSDSESESLAPRKTE S57
T74-p
EEEELEEtAQEKKLR
Upstream
0 4
Treatment
  • ZK-Thiazolidinone
RNU3IP2 (human) EEEELEEtAQEKKLR T74-p
RNU3IP2 (mouse) EEEELEETAQEKKLR T74
RNU3IP2 (rat) EEEELEETAQEKKLR T74
K113-ub
DQVAGRLkEDVLEQR
0 3
RNU3IP2 (human) DQVAGRLkEDVLEQR K113-ub
RNU3IP2 (mouse) DQVAGRLKEDVLEQR K113
RNU3IP2 (rat) DQVAGRLKEDVLEQR K113
K125-ub
EQRGRLQkLVAkEIQ
0 1
RNU3IP2 (human) EQRGRLQkLVAkEIQ K125-ub
RNU3IP2 (mouse) EQRGRLQKSVAKEIQ K125
RNU3IP2 (rat) EQRGRLQKLVAKEIQ K125
K129-ub
RLQkLVAkEIQAPAS
0 5
RNU3IP2 (human) RLQkLVAkEIQAPAS K129-ub
RNU3IP2 (mouse) RLQKSVAKEIQAPAP K129
RNU3IP2 (rat) RLQKLVAKEIQAPAP K129
S169
FSAAKDCSIIKWSVE
0 1
RNU3IP2 (human) FSAAKDCSIIKWSVE S169
RNU3IP2 (mouse) FSAAKDCtIIKWSVE T169-p
RNU3IP2 (rat) FSAAKDCTIIKWSVE T169
K180-ub
WSVESGRkLHVIPRA
0 1
RNU3IP2 (human) WSVESGRkLHVIPRA K180-ub
RNU3IP2 (mouse) WSVETGRKLHVIPRA K180
RNU3IP2 (rat) WSVETGRKLHVIPRA K180
S245-p
TGHRDAVsGLAFRRG
0 1
RNU3IP2 (human) TGHRDAVsGLAFRRG S245-p
RNU3IP2 (mouse) TGHRDAVSGLAFRKG S245
RNU3IP2 (rat) TGHRDAVSGLAFRRG S272
K266
TSHDRSVKVWNVAEN
0 1
RNU3IP2 (human) TSHDRSVKVWNVAEN K266
RNU3IP2 (mouse) TSHDRSVkVWNAAEN K266-ac
RNU3IP2 (rat) TSHDRSVKVWNAAEN K293
K355-ub
ALWGLSKkRPLALQR
0 1
RNU3IP2 (human) ALWGLSKkRPLALQR K355-ub
RNU3IP2 (mouse) ALWGLSKKRPLALQR K355
RNU3IP2 (rat) ALWGLSKKRPLALQR K382
P470
PLRRVPVPPAAGs__
0 36
RNU3IP2 (human) PLRRVPVPPAAGs__ P470
RNU3IP2 (mouse) PLRRLPVsPVAGS__ S470-p
RNU3IP2 (rat) PLRRVPVsPVAGS__ S497-p
S475-p
PVPPAAGs_______
0 3
RNU3IP2 (human) PVPPAAGs_______ S475-p
RNU3IP2 (mouse) PVsPVAGS_______ S475
RNU3IP2 (rat) PVsPVAGS_______ S502